The role of tigecycline in the management of Clostridium difficile infection: a retrospective cohort study

Clinical Microbiology and Infection

Volumn 24, Issue 2, 2018, Pages 180-184

  Manea, E ^a,b   Sojo Dorado, J ^c   Jipa, R E ^a,b   Benea, S N ^a,b   Rodriguez Bano J ^c   Hristea, A ^a,b  

^a Professor Dr Matei Bals National Institute of Infectious Diseases   (Romania)

^b CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^c Instituto de Biomedicina de Sevilla   (Spain)

Author keywords

Clostridium difficile; Outcome; Propensity score; Recurrence; Tigecycline

Indexed keywords

ALBUMIN; ANTIBIOTIC AGENT; CREATININE; TIGECYCLINE PLUS VANCOMYCIN; UNCLASSIFIED DRUG; VANCOMYCIN; ANTIINFECTIVE AGENT; MINOCYCLINE; TIGECYCLINE;

ABDOMINAL INFECTION; ACUTE KIDNEY FAILURE; ADULT; AGE; AGED; ANTIBIOTIC THERAPY; ARTICLE; ATLAS SCORE; BONE AND JOINT INFECTIONS; CARDIOVASCULAR DISEASE; CHARLSON COMORBIDITY INDEX; CHRONIC RESPIRATORY TRACT DISEASE; CLINICAL OUTCOME; CLOSTRIDIUM DIFFICILE INFECTION; COHORT ANALYSIS; COMBINATION DRUG THERAPY; COMORBIDITY; COMPARATIVE EFFECTIVENESS; CONCURRENT INFECTION; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE SEVERITY; DISEASE SEVERITY ASSESSMENT; FEMALE; FEVER; HEMATOLOGIC MALIGNANCY; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; INFECTION RATE; INFECTION RISK; KIDNEY FAILURE; LEUKOCYTE COUNT; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASM; MONOTHERAPY; OBSERVATIONAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROPENSITY SCORE; RECURRENCE RISK; RECURRENT INFECTION; RESPIRATORY TRACT INFECTION; RETROSPECTIVE STUDY; SEX; SKIN INFECTION; TOXIC MEGACOLON; TREATMENT RESPONSE; URINARY TRACT INFECTION; ANALOGS AND DERIVATIVES; DRUG EFFECT; MIDDLE AGED; PEPTOCLOSTRIDIUM DIFFICILE; PSEUDOMEMBRANOUS COLITIS; RETROGNATHIA; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FEMALE; HUMANS; MALE; MIDDLE AGED; MINOCYCLINE; POLYMERASE CHAIN REACTION; RETROGNATHIA; VANCOMYCIN;

EID: 85026285720     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1016/j.cmi.2017.06.005     Document Type: Article

References (16)

1. Reveles, K.R., Lee, G.C., Boyd, N.K., Frei, C.R., The rise in Clostridium difficile infection incidence among hospitalized adults in the United States: 2001–2010. Am J Infect Control 42 (2014), 1028–1032.
2. Vindigni, S.M., Surawicz, C.M., C. difficile Infection: changing Epidemiology and management paradigms. Clin Transl Gastroenterol, 6, 2015, e99.
3. Debast, S.B., Bauer, M.P., Kuijper, E.J., European society of clinical microbiology and Infectious diseases: update of the treatment guidance document for Clostridium difficile Infection. Clin Microbiol Infect 20 (2014), 1–26.
4. Stuart, H.C., Dale, N.G., Stuart, J., Ciaran, P.K., Vivian, G.L., McDonald, L.C., et al. Clinical practice guidelines for Clostridium difficile Infection in adults: 2010 update by the society for healthcare Epidemiology of America (SHEA) and the Infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 31 (2010), 431–455.
5. Surawicz, C.M., Brandt, L.J., Binion, D.G., Ananthakrishnan, A.N., Curry, S.R., Gilligan, P.H., et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile Infections. Am J Gastroenterol 108 (2013), 478–498 quiz499.
6. Britt, N.S., Steed, M.E., Potter, E.M., Clough, L.A., Tigecycline for the treatment of severe and severe complicated Clostridium difficile Infection. Infect Dis Ther 3 (2014), 321–331.
7. Nord, C.E., Sillerstrom, E., Wahlund, E., Effect of tigecycline on normal oropharyngeal and intestinal microflora. Antimicrob Agents Chemother 50 (2006), 3375–3380.
8. Aldape, M.J., Heeney, D.D., Bryant, A.E., Stevens, D.L., Tigecycline suppresses toxin A and B production and sporulation in Clostridium difficile. J Antimicrob Chemother 70 (2015), 153–159.
9. Garneau, J.R., Valiquette, L., Fortier, L.C., Prevention of Clostridium difficile spore formation by sub-inhibitory concentrations of tigecycline and piperacillin/tazobactam. BMC Infect Dis, 14, 2014, 29.
10. Bassis, C.M., Theriot, C.M., Younga, V.B., Alteration of the murine gastrointestinal microbiota by tigecycline leads to increased susceptibility to Clostridium difficile infection. Antimicrob Agents Chemother 58:5 (2014), 2767–2774.
11. Gergely Szabo, B., Kadar, B., Szidonia Lenart, K., Dezsenyi, B., Kunovszki, P., Fried, K., et al. Use of intravenous tigecycline in patients with severe Clostridium difficile infection: a retrospective observational cohort study. Clin Microbiol Infect 22 (2016), 990–995.
12. Crobach, M.J.T., Planche, T., Eckert, C., Barbut, F., Terveer, E.M., Dekkers, O.M., et al. European Society of Clinical Microbiology and infectious Diseases: update of the diagnostic guidance document for Clostridium difficile infection. Clin Microbiol Infect 22:s4 (2016), s63–s81.
13. Miller, M.A., Louie, T., Mullane, K., Derivation and validation of a simple clinical bedside score (ATLAS) for Clostridium difficile infection, which predicts response to therapy. BMC Infect Dis, 13, 2013, 148.
14. McDonald, L.C., Coignard, B., Dubberke, E., Song, X., Horan, T., Kutty, P.K., Ad hoc Clostridium difficile surveillance working group. Recommendations for surveillance of Clostridium difficile-associated disease. Infect Control Hosp Epidemiol 2 (2007), 140–145.
15. Charlson, M.E., Pompei, P., Ales, K.L., MacKenzie, C.R., A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:5 (1987), 373–383.
16. Bone, R.C., Balk, R.A., Cerra, F.B., Dellinger, R.P., Fein, A.M., Knaus, W.A., et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM consensus conference committee. American college of chest physicians/society of critical care medicine. Chest 101:6 (1992 Jun), 1644–1655.